POISE I Pilot Study

Overview

POISE I study is a feasibility study for evaluating the safety and efficacy of DCB.

Full Title of Study: “Paclitaxel-Coated Balloon for the Treatment of Symptomatic Recurrent Benign Intestinal Stricture”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2020

Detailed Description

The study is designed to determine the safety and effectiveness for drug coated balloon (DCB) for treating intestinal strictures. Up to 15 subjects are planned to be enrolled and treated with the study device at up to 5 clinical sites outside of US. Subjects will be followed up post-treatment to one year and then annually for up to 5 years. The annual follow up after the first year is optional.

Interventions

  • Combination Product: GIE Medical Drug Coated Balloon
    • Stricture patients treated by DCB

Arms, Groups and Cohorts

  • Experimental: DCB Treatment
    • Stricture patients treated by DCB

Clinical Trial Outcome Measures

Primary Measures

  • Incident of serious balloon dilation-related complications
    • Time Frame: 30 days
    • Perforation, bleeding requiring endoscopic or surgical interventions or blood transfusion, severe abdominal pain requiring medications, infection requiring hospitalization or IV antibiotics

Secondary Measures

  • Procedure success
    • Time Frame: 6 months
    • defined as subjects who were treated with GIE DCB achieved at least one scale improvement of the Endoscopic Obstructive Scale (EOS).
  • Percent subjects with improvement in Endoscopic Obstructive Scale (EOS)
    • Time Frame: 6 months
    • Analyzed by 1, 2, or 3 scale improvement.
  • Change in obstructive symptoms using the Obstructive Symptom Score (OSS).
    • Time Frame: 30 days, 3 months, 6 months, and 12 months
    • The Obstructive Symptom Score (OSS) is a composite measure of the total number of days of obstructive abdominal pain and the severity over a fourteen-day period using a 5-point Likert scale. (1=no pain, 2=mild, 3=moderate, 4=severe, 5=unbearable).
  • Number of repeated stricture dilation procedures
    • Time Frame: 30 days, 3 months, 6 months, and 12 months
    • Repeat dilation for stricture recurrence
  • Procedural technical success
    • Time Frame: Time of procedure
    • Successful endoscopic passage followed by successful delivery of the drug-coated balloon to the stricture area without resistance, inflated balloon to the defined diameter, DCB withdraw after deflating balloon without device malfunction.

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥ 18 and ≤ 80 years. 2. Subjects for whom the balloon dilation would be chosen in standard practice, and the scope could not pass stricture. 3. Recurrent to plain balloon dilation with at least 2 previous balloon dilation or stricturotomy sessions and recurrence of intestine obstructive symptoms/signs. 4. Symptoms of intestinal partial occlusion 5. Length of stenosis/stricture ≤ 7 cm 6. Up to 2 discrete strictures. 7. Ability to undergo periodic endoscopic follow-up. 8. Voluntary participation and provided written informed consent. Exclusion Criteria:

1. Pregnancy or breastfeeding or plan to get pregnant in next 12 months. 2. Contraindication to endoscopy, anesthesia or deep sedation. 3. Malignant bowel stricture. 4. Extrinsic benign bowel stricture due to adhesion. 5. Stricture complicated with abscess, fistula, ulceration or associated with mesenteric vessel thrombosis 6. More than 2 stenosis/stricture lesions. 7. Length of stenosis/stricture > 7 cm. 8. Stricture not accessible by endoscopy. 9. Suspected perforation of the gastrointestinal tract 10. Acute bowel obstruction requiring urgent surgical intervention 11. Low rectal or anal strictures 12. Severe coagulation disorders (platelets < 70000; INR > 1.8). 13. Active systemic infection 14. Allergy to paclitaxel or any components of the delivery system. 15. Life expectancy of less than 12 months. 16. Drug abuse or on chronic steroid therapy for comorbidities. 17. Unwilling or unable to comply with the follow-up study requirements. 18. Lacking capacity to provide informed consent. 19. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety. 20. Currently participation in another pre-market drug or medical device clinical study. 21. Chronic steroid use for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use. 22. Currently requiring abdominal radiation therapy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • GIE Medical
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bo Shen, MD, Principal Investigator, The Cleveland Clinic
  • Overall Contact(s)
    • Peter Barnett, MS, 763-219-8902, barnettp@giemedical.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.